As of late May 2022, it was announced that Halozyme (NASDAQ: HALO) had completed its acquisition of Antares Pharma, Inc., creating a leading drug delivery business with broadly licensable opportunities across the ENHANZE® and Antares auto injector technologies. Antares Pharma Inc - formerly known as Medi-Ject Corporation - functioned as a drug delivery company focused on developing, manufacturing and marketing needle-free injection systems for the self-administration of a wide range of parenteral drugs. The firm's technology is grounded in Needle-free drug delivery injection system use of a narrow, high-pressure stream of liquid. With only a minimal SBIR involvement - and that some years ago - the firm's Medi-Jector Vision system is a handheld device that injects a thin, high-pressure stream of liquid, eliminating the need for a needle. The Vision system is used primarily for the delivery of insulin and of human growth hormones for children; it is available over-the-counter and by prescription in the US and is also sold overseas. Antares was formed when Medi-Ject completed a reverse acquisition of Permatec,
